Idera Pharmaceuticals, Inc. (IDRA): Price and Financial Metrics


Idera Pharmaceuticals, Inc. (IDRA): $0.69

0.00 (-0.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IDRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

IDRA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for IDRA is -10.06 -- better than only 1.79% of US stocks.
  • IDRA's price/sales ratio is 43.02; that's higher than the P/S ratio of 95.46% of US stocks.
  • As for revenue growth, note that IDRA's revenue has grown 255.77% over the past 12 months; that beats the revenue growth of 97.36% of US companies in our set.
  • Stocks that are quantitatively similar to IDRA, based on their financial statements, market capitalization, and price volatility, are SURF, NXTC, MVIS, CRUS, and MCRB.
  • IDRA's SEC filings can be seen here. And to visit Idera Pharmaceuticals Inc's official web site, go to www.iderapharma.com.

IDRA Stock Price Chart Interactive Chart >

Price chart for IDRA

IDRA Price/Volume Stats

Current price $0.69 52-week high $6.14
Prev. close $0.69 52-week low $0.60
Day low $0.67 Volume 402,000
Day high $0.69 Avg. volume 1,799,488
50-day MA $0.91 Dividend yield N/A
200-day MA $1.53 Market Cap 36.43M

Idera Pharmaceuticals, Inc. (IDRA) Company Bio


Idera Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. The company was founded in 1989 and is based in Cambridge, Massachusetts.


IDRA Latest News Stream


Event/Time News Detail
Loading, please wait...

IDRA Latest Social Stream


Loading social stream, please wait...

View Full IDRA Social Stream

Latest IDRA News From Around the Web

Below are the latest news stories about Idera Pharmaceuticals Inc that investors may wish to consider to help them evaluate IDRA as an investment opportunity.

Head-To-Head Contrast: Tarsus Pharmaceuticals (NASDAQ:TARS) and Idera Pharmaceuticals (NASDAQ:IDRA)

Tarsus Pharmaceuticals (NASDAQ:TARS) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation. Analyst Recommendations This is a summary of recent recommendations for Tarsus Pharmaceuticals and Idera Pharmaceuticals, []

Transcript Daily | November 13, 2021

Critical Contrast: Idera Pharmaceuticals (NASDAQ:IDRA) and Tarsus Pharmaceuticals (NASDAQ:TARS)

Idera Pharmaceuticals (NASDAQ:IDRA) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings. Analyst Ratings This is a summary of current ratings and price targets for Idera Pharmaceuticals []

Dakota Financial News | November 13, 2021

Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021. “We are maintaining our focus on identifying new development or commercial-stage assets for Idera’s portfolio and we are encouraged by the opportunities presented to us,” stated Vincent Milano, Idera’s Chief Executive Officer. “As a number of these prospects adva

Yahoo | November 8, 2021

Idera Pharmaceuticals (NASDAQ:IDRA) and Bavarian Nordic A/S (OTCMKTS:BVNRY) Critical Analysis

Idera Pharmaceuticals (NASDAQ:IDRA) and Bavarian Nordic A/S (OTCMKTS:BVNRY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership. Insider and Institutional Ownership 11.7% of Idera Pharmaceuticals shares are held by institutional investors. 5.1% []

Transcript Daily | November 4, 2021

Idera Pharmaceuticals Inc. (NASDAQ:IDRA): -597.73% Off High, Can It Comeback?

In last trading session, Idera Pharmaceuticals Inc. (NASDAQ:IDRA) saw 0.42 million shares changing hands with its beta currently measuring 1.71. Companys recent per share price level of $0.88 trading at $0.0 or -0.64% at ring of the bell on the day assigns it a market valuation of $47.61M. That closing price of IDRAs stock is Idera Pharmaceuticals Inc. (NASDAQ:IDRA): -597.73% Off High, Can It Comeback? Read More »

Marketing Sentinel | October 23, 2021

Read More 'IDRA' Stories Here

IDRA Price Returns

1-mo -18.83%
3-mo -36.70%
6-mo -40.52%
1-year -83.92%
3-year -89.96%
5-year -94.90%
YTD -81.20%
2020 101.65%
2019 -34.30%
2018 -83.59%
2017 40.67%
2016 -51.46%

Continue Researching IDRA

Want to see what other sources are saying about Idera Pharmaceuticals Inc's financials and stock price? Try the links below:

Idera Pharmaceuticals Inc (IDRA) Stock Price | Nasdaq
Idera Pharmaceuticals Inc (IDRA) Stock Quote, History and News - Yahoo Finance
Idera Pharmaceuticals Inc (IDRA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7667 seconds.